Biotechnology, Wellness & the Science of Aging | #𝐒𝐀𝐋𝐓𝐍𝐘

TL;DR

Biotech experts discuss the future of aging and longevity, including building successful biotech companies and investing in the field.

Transcript

well welcome everyone to another longevity panel and this time we're going to focus a bit on biotech how do we set build successful biotech companies in the field of aging and then how do we invest in the age of aging as i like to call this period where we have long living but not necessarily healthy population so i'm joined on stage by james pyre ... Read More

Key Insights

• 🤕 Aging is a complex process with effects at every level of organization, from DNA mutations to tissue and organ dysfunction.
• 😃 The biggest challenge for longevity biotech companies is demonstrating the efficacy of aging interventions without waiting for decades to observe changes in health outcomes.
• 💆 Developing surrogate biomarkers of age-related disease risk is crucial for speeding up clinical trials and getting aging therapies approved.
• 🥹 Company structure plays a significant role in the longevity biotech space, with options ranging from traditional single-company structures to holding companies and platform models.

Questions & Answers

Q: What are the main focuses of each panelist's company in the field of aging?

James Pyre's company, Cambrian Biopharma, focuses on developing therapies that target fundamental aging pathways. Nathaniel David's company, Unity, develops medicines that eliminate old cells associated with aging-related diseases. Kristen Fortney's company, BioAge Labs, is developing therapies to treat diseases of aging and extend healthy lifespan.

Q: How do biomarkers play a role in assessing the effects of aging interventions?

Biomarkers provide a way to measure the changes in biological age and disease risk over a shorter period of time. They can help determine the efficacy of interventions and serve as a surrogate endpoint in clinical trials.

Q: What is the best company structure for a longevity-focused biotech company?

There are different approaches, including a traditional single company structure, a holding company model with subsidiaries, and a platform model. The choice depends on the company's strategy, goals, and available resources.

Q: How do longevity companies choose the right indication for their drugs in clinical trials?

Longevity companies often start with diseases that are strongly linked to aging, such as arthritis or diseases of the aging retina. By targeting these diseases, they can observe the impact of their interventions on the underlying aging process. The goal is to ultimately expand the indications for these drugs.

Summary & Key Takeaways

• The panel consists of biotech founders and CEOs discussing their respective companies and the exciting work they are doing in the field of aging.

• Each panelist shares their unique approach to targeting the underlying causes of aging and developing therapies that address diseases of aging.

• Biomarkers play a crucial role in assessing the efficacy of aging interventions and speeding up clinical trials.

• The panelists discuss different company structures, including a holding company model and a platform model, and the advantages they offer in the longevity biotech space.